Context Therapeutics (CNTX)

Executive Summary

Context Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation T cell engager (TCE) bispecific antibodies for solid tumors. The company has pivoted from its legacy onapristone-based endocrine therapies to a pipeline of novel TCEs targeting CLDN6, MSLN, and Nectin-4, aiming to overcome limitations in solid tumor immunotherapy. Lead programs include CT-95 (anti-MSLN TCE) and CTIM-76 (anti-CLDN6 TCE), both in Phase 1 dose-escalation trials. CT-95 is recruiting for mesothelin-expressing tumors including ovarian, pancreatic, and mesothelioma, with initial data expected in 2026. CTIM-76 targets CLDN6-positive ovarian, testicular, and endometrial cancers, with early clinical data also anticipated in 2026-2027. The company's TCE platform utilizes proprietary bispecific formats designed to enhance tumor penetration and reduce toxicity. While still early-stage, Context represents a pure-play on TCEs in solid tumors, a space with significant unmet need and recent validation from competitors. The success of its pipeline hinges on demonstrating safety and preliminary efficacy in dose-escalation cohorts, as well as securing additional financing or partnerships to support further development.

Upcoming Catalysts (preview)

• H2 2026Initial Phase 1 data for CT-95 (anti-MSLN TCE)25% success
• H2 2026Initial Phase 1 data for CTIM-76 (anti-CLDN6 TCE)30% success
• TBDPotential partnership or licensing deal for TCE platform20% success